PoreWise One finding · Official ingredient listing
Document title
CosIng — European Commission cosmetic ingredient database
- Kind of evidence
- Official ingredient listing
- Measured outcome
- Legal limits
- Year
- Who was studied
- Sample size
- Measured outcome
- UV filters are permitted up to the maximum concentrations set by each market's regulation.
- Certainty
- High
- Who was measured
- Products making a sunscreen claim. Limits differ between the EU, the US and China.
- Study limits
- Reapplication and the amount applied matter more than the label. · Ingredient database · AVOBENZONE · HOMOSALATE · OCTISALATE
Where it comes from
- CosIng — European Commission cosmetic ingredient database
Published by European Commission · Last checked 2026-10-12
Ingredients it was measured on
Other findings on the same ingredient or concern
- Skin effectSunscreen and prevention of skin aging: a randomized trial
In a randomized controlled community trial of 903 adults under 55, daily use of a broad-spectrum SPF 15+ sunscreen slowed skin aging over 4.5 years: the daily-sunscreen group showed 24% less photoaging than the discretionary-use group (relative odds 0.76, 95% CI 0.59 to 0.98). The trial measured the act of using a broad-spectrum sunscreen.
Human trial · 2013 · 903 people · adults under 55 in Nambour, Australia · Daily use of a broad-spectrum sunscreen in adults under 55 living in a high-UV climate. · The trial assigned a broad-spectrum sunscreen. It ran in Australia at a high-UV latitude and stopped at 4.5 years, and the relative effect was modest (24%).
- Skin effectThe Influence of Sunscreen Use on Skin Pigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Vitiligo
A 2026 review of the 2015-2025 literature concluded that sun protection plays a central role in the prevention and treatment of pigmentation disorders including melasma and post-inflammatory hyperpigmentation, and that broad-spectrum sunscreens with visible-light protection may enhance protection against hyperpigmentation.
Review article · 2026 · People with melasma, post-inflammatory hyperpigmentation or vitiligo · People managing or preventing pigmentation disorders, particularly melasma and post-inflammatory hyperpigmentation; those with darker skin phototypes (IV-VI) where visible light can worsen hyperpigmentation. · 2026 · People with melasma, post-inflammatory hyperpigmentation or vitiligo. · PMID 42793277